貨號(hào)：GS40481

Nurulimab (also known as BCD?145) is a human IgG1?kappa monoclonal antibody that targets cytotoxic T?lymphocyte?associated protein 4 (CTLA?4, CD152), an inhibitory immune checkpoint receptor. As an IgG1 isotype, it is designed to engage immune effector functions such as antibody?dependent cellular cytotoxicity (ADCC) and complement?dependent cytotoxicity (CDC). By binding to CTLA?4, nurulimab blocks the interaction between CTLA?4 and its ligands B7?1 (CD80) and B7?2 (CD86), thereby reversing CTLA?4?mediated suppression of T?cell activation. This action enhances T?cell priming and may deplete regulatory T cells (Tregs) in the tumor microenvironment, promoting anti?tumor immunity. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors.